01—Abstract
Summary
Summary of the 8-K filed May 30, 2025. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation (MCK) completed a $2.0 billiona senior unsecured notes offering, with the notes issued May 30, 2025 under its existing February 2023 indenture.
The offering consisted of $650 millionb of 4.650% notes due 2030, $650 million of 4.950% notes due 2032, and $700 million of 5.250% notes due 2035. The Company received approximately $1,989.7 million in net proceeds after the underwriting discount, before estimated offering expenses. Pricing was tight to Treasuries, at spreads of roughly +60 to +80 basis points, which suggests solid investor demand for MCK credit.
The primary purpose of the offering is to fund the acquisition of a 70%c controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (CORE Ventures), an internal business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC. The Company intends to fund the deal with the note proceeds, cash on hand, and/or commercial paper borrowings. The filing does not disclose the purchase price, so investors cannot yet gauge the acquisition's size relative to the company's cash flows or the effect on leverage.
The notes are unsecured and rank equally with the Company's other unsecured senior debt, and they carry customary covenants on liens and sale-leaseback transactions, along with a 101% change-of-control put that is triggered only if the notes are also downgraded below investment grade by all rating agencies. From a capital structure perspective, the offering adds about $2.0 billiond of fixed-rate debt with staggered maturities, extending McKesson's maturity profile.
The pricing term sheet lists ratings of A3 (Stable) from Moody's, BBB+ (Positive) from S&P, and A- (Stable) from Fitch, which indicates a solid investment-grade profile. Investors should watch for the acquisition's financial terms and any resulting change in leverage or commercial paper usage in future filings.
02—Key points
Key Highlights
- Issued $2.0 billion of senior unsecured notes on May 30, 2025: $650M 4.650% due 2030, $650M 4.950% due 2032, and $700M 5.250% due 2035.
- Net proceeds of approximately $1,989.7 million before estimated offering expenses.
- Proceeds, together with cash on hand and/or commercial paper, will fund the acquisition of a 70% controlling interest in CORE Ventures, a business services entity tied to Florida Cancer Specialists & Research Institute.
- Pricing was tight to Treasuries, at spreads of +60, +70, and +80 basis points, with issue prices of 99.960%, 99.930%, and 99.777% of par.
- Notes are unsecured and rank pari passu with existing unsecured senior debt; covenants limit liens and sale-leaseback transactions and restrict consolidations, mergers, or asset sales.
- Change-of-control put at 101% applies only if a change of control and a downgrade below investment grade by all rating agencies both occur within a specified period.
- Ratings in the pricing term sheet are A3 (Stable) by Moody's, BBB+ (Positive) by S&P, and A- (Stable) by Fitch.
03—Questions
Frequently Asked Questions
How much debt did McKesson raise and what are the terms?
McKesson issued $2.0 billion of senior unsecured notes in three tranches: $650 million of 4.650% notes due May 30, 2030, $650 million of 4.950% notes due May 30, 2032, and $700 million of 5.250% notes due May 30, 2035. Interest is paid semi-annually on May 30 and November 30, beginning November 30, 2025.
What is the money being used for?
The Company plans to use the net proceeds, together with cash on hand and/or commercial paper borrowings, to fund the acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (CORE Ventures). The filing does not disclose the purchase price or the expected financial impact of the acquisition.
Can McKesson redeem the notes early?
Yes. Before the par call dates (April 30, 2030 for the 2030 notes, March 30, 2032 for the 2032 notes, and March 1, 2035 for the 2035 notes), the Company may redeem at a make-whole price based on the Treasury rate plus 10 basis points for the 2030 notes and 15 basis points for the 2032 and 2035 notes. From the par call dates onward, redemption is at par plus accrued interest.
Does this debt create investor protections or risks I should know about?
The notes carry covenants limiting liens on assets, sale-leaseback transactions, and certain consolidations, mergers, or asset sales, subject to exceptions in the indenture. A 101% change-of-control repurchase right applies only if a change of control and a downgrade below investment grade by each rating agency both occur within a specified period. The notes are unsecured, so holders have no collateral claim.
How does this offering affect McKesson's credit profile?
The filing lists ratings of A3 (Stable) from Moody's, BBB+ (Positive) from S&P, and A- (Stable) from Fitch, which are solidly investment grade. The offering adds roughly $2.0 billion of fixed-rate debt. The overall leverage impact will depend on the acquisition's size and cash flow contribution, which the filing does not quantify.
04—Continue